Patents Assigned to Institut National de la Sante
-
Publication number: 20240010739Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.Type: ApplicationFiled: November 10, 2021Publication date: January 11, 2024Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hopitaux de Paris (APHP), Baylor Research Institute, Universite Paris Est Creteil Val De MarneInventors: Yves LEVY, Gérard ZURAWSKI, Mireille CENTLIVRE, Sandra ZURAWSKI, Véronique GODOT
-
Patent number: 11865185Abstract: The invention is directed to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. The present invention further relates to a method for chemically coupling an Adeno-Associated Virus (AAV) vector particle with at least one ligand L and to a Recombinant Adeno-Associated Virus (rAAV) vector particle obtained by said method as well as a pharmaceutical composition comprising it and their corresponding medical use.Type: GrantFiled: June 9, 2017Date of Patent: January 9, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), NANTES UNIVERSITE, CENTRE HOSPITALIER UNIVERSITAIRE DE NANTESInventors: Mathieu Mevel, David Deniaud, Eduard Ayuso
-
Patent number: 11866484Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: GrantFiled: March 3, 2021Date of Patent: January 9, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Patent number: 11865189Abstract: The present invention relates to methods and composition for use in the treatment of retinal degeneration, in particular retinal degeneration due to retinal pigment epithelium dysfunction.Type: GrantFiled: December 17, 2015Date of Patent: January 9, 2024Assignees: SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)Inventors: Thierry Leveillard, Christo Kole, Jose-Alain Sahel
-
Publication number: 20240002521Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERAAN BIOTECHNOLOGY, UNIVERSITE D'AIX MARSEILLE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
-
Publication number: 20240002522Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERANN BIOTECHNOLOGY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE, UNIVERSITE PARIS CITE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jerome GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
-
Patent number: 11857532Abstract: Friedreich ataxia (FRDA) is caused by a GAA repeat expansion in FXN gene that encodes a mitochondrial protein, frataxin, involved in iron sulfur complex (ISC) assembly. Frataxin deficiency results in abnormal ISC containing proteins, namely respiratory chain complex I-III and aconitases and accumulation of iron in brain and heart of patients. Here, the inventors show that FRDA fibroblasts are unable to limit iron uptake inducing a massive cytosolic iron accumulation and to a lesser extent in mitochondria. The inventors also observed increased transferrin receptor (TfR1) steady state levels and membrane TfR1 accumulation that they ascribed to impaired post-translational modification by palmitoylation as well as delayed transferrin recycling. Finally, the inventors showed that artesunate, dichloroacetate and Coenzyme-A improved TfR1 palmitoylation and thus represent candidate molecules for the treatment of patients with Friedreich ataxia.Type: GrantFiled: December 27, 2019Date of Patent: January 2, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), FONDATION IMAGINE, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)Inventors: Anne Agnès Rotig, Arnold Munnich, Floriane Petit
-
Patent number: 11852704Abstract: The present disclosure is directed to a motor for a magnetic resonance (MR) tomography room, to a patient table for the MR room, to a MR elastography device, and to a MR tomography device. A MR tomography device for a MR elastography imaging protocol is arranged within the MR tomography room, and includes a rotational drive for supplying rotational energy to power a MR elastography transducer usable during the MR elastography imaging protocol, and a support structure. The rotational drive comprises a terminal for connecting the MR elastography transducer to the rotational drive, and a bearing means configured such that the position of the terminal relative to the support structure is adaptable along a trajectory predetermined by the bearing means. The rotational drive is mounted to the support structure via the bearing means.Type: GrantFiled: March 17, 2022Date of Patent: December 26, 2023Assignees: Siemens Healthcare GmbH, Centre National de la Recherche Scientifique (CNRS), Institut National de La Sante et de la Recherche Medicale (INSERM), King's College London, Department of Health and Human Services, UNIV PARIS XIII PARIS-NORD VILLETANEUSE, Universite de ParisInventors: Giacomo Annio, Verena Muller-Reinwald, Ralph Sinkus, Omar Darwish, Wilfried Schnell, Tamara Elisabeth Falkner, Ahmed M. Gharib
-
Publication number: 20230407264Abstract: The present invention relates to a population of cells comprising hepatic stem-like cells and therapeutic use thereof, for the treatment and the prevention of fulminant liver disorders. The hepatic stem-like cells according to the invention may be safely and reproducibly generated from pluripotent stem cells. In addition, although the hepatic stem-like cells according to the invention do not display the phenotype of physiologically mature hepatic cells, as they are lacking the albumin expression marker (ALB?), they may still be transplanted in a diseased liver with acute failure, rescue the diseased liver and promote liver regeneration. Moreover, various protocols of preparation of hepatic stem-like cells according to the invention may be implemented, all resulting in high quality and high yield of production. Finally, the hepatic stem-like cells according to the invention may be cryopreserved and may also be prepared as spheroid particles.Type: ApplicationFiled: March 15, 2021Publication date: December 21, 2023Applicants: Goliver Therapeutics, Nantes Universite, Institut National de la Santé et de la Recherche MédicaleInventors: Tuan Huy Nguyen, Angélique Fourrier, Raphaël Rispal, Frédéric Delbos
-
Patent number: 11839630Abstract: The present invention is relative to an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antibody or antibody fragment which includes a anti-IL-1RAP binding domain, polypeptides encoded by this nucleic acid molecule, isolated chimeric antigen receptor (CAR) molecule comprising such an antibody or antibody fragment, a vector comprising a nucleic acid molecule encoding a CAR, as well as a T cell comprising this vector. The present invention is also relative to the use of this T cell (autologous or allogeneic) expressing a CAR molecule to treat a proliferative disease in a mammal.Type: GrantFiled: November 14, 2018Date of Patent: December 12, 2023Assignees: ETABLISSEMENT FRANCAIS DU SANG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE, CENTRE HOSPITALIER UNIVERSITAIRE DE BESANCON, UNIVERSITE DE FRANCHE COMTEInventors: Christophe Ferrand, Marina Deschamps, Fabrice Larosa
-
Publication number: 20230393152Abstract: An identification of novel combinations of specific metabolites for neurodegenerative diseases for use as biomarkers in the early diagnosis of neurodegenerative diseases.Type: ApplicationFiled: November 18, 2021Publication date: December 7, 2023Applicants: UNIVERSITE GRENOBLE ALPES, INSERM - Institut National de la Santé et de la Recherche MédicaleInventors: Sabrina BOULET, Florence FAUVELLE, David MALLET
-
Publication number: 20230382991Abstract: An antagonist antibody, or an antigen binding fragment thereof, binds both to human and macaque LILRB1 and/or LILRB2, and has diagnostic and therapeutic uses.Type: ApplicationFiled: October 12, 2021Publication date: November 30, 2023Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITE PARIS SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Benoit FAVIER, Sixtine COINDRE, Anne WIJKHUISEN, Stéphanie SIMON, Roger LE GRAND, Olivier LAMBOTTE
-
Publication number: 20230384312Abstract: A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.Type: ApplicationFiled: October 22, 2021Publication date: November 30, 2023Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, UNIVERSITE D'ANGERS, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Maria del Carmen MARTINEZ, Pierre BIGOT, Luisa VERGORI
-
Patent number: 11826403Abstract: The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by ?PKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of ?PKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of ?PKC on ALMS1.Type: GrantFiled: October 20, 2020Date of Patent: November 28, 2023Assignees: UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, VAXINE PTY LTDInventors: Vincent Marion, Nikolai Petrovsky
-
Patent number: 11827747Abstract: The present invention concerns a polymer comprising repetitive units having the following formula (I) wherein R1 is H or Me; L is a linker; R2 is the side chain of an ?-amino acid being other than arginine; m is 0 or an integer comprised from 1 to 10; n is an integer comprised from 1 to 10; and X— is a counterion.Type: GrantFiled: May 6, 2020Date of Patent: November 28, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE STRASBOURGInventors: Fouzia Boulmedais, Delphine Chan-Seng, Nicolas Zydziak, Philippe Lavalle
-
Patent number: 11827637Abstract: The present invention concerns a compound of formula (I): or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity, in particular ERK2 activity.Type: GrantFiled: January 13, 2023Date of Patent: November 28, 2023Assignees: AGV Discovery, Institut National de la Sante et de la Recherche Medicale (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Université De MontpellierInventors: Cédric Bories, Loïc Mathieu, Jean-François Guichou, Muriel Gelin, Aurélien Biechy
-
Publication number: 20230372350Abstract: A TRPA1 calcium channel inhibitor for use as a neuroprotectant in the treatment and/or prevention of the early stages of Alzheimer's disease and as an anti-inflammatory in the treatment and/or prevention of neuroinflammatory processes in Alzheimer's disease. In particular, the inhibitor HC030331 of the TRPA1 calcium channel for its use as a neuroprotectant in the treatment and/or prevention of the early stages of Alzheimer's disease and as an anti-inflammatory in the treatment and/or the prevention of the neuroinflammatory processes of Alzheimer's disease. A pharmaceutical composition comprising at least the inhibitor of the invention and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: September 17, 2021Publication date: November 23, 2023Applicants: UNIVERSITE GRENOBLE ALPES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Mireille ALBRIEUX, Adrien PAUMIER, Anthony BOSSON, Alain BUISSON, Sylvie BOISSEAU
-
Publication number: 20230372416Abstract: A combination of agents capable of binding an infectious agent, such as an antibody, an antibody derivative, or an antibody mimetic, and immunomodulatory agents, such as probiotic strains, for the treatment or prevention of respiratory infections, in particular bacterial respiratory infections. The agents capable of binding an infectious agent are administered by inhalation.Type: ApplicationFiled: October 8, 2021Publication date: November 23, 2023Applicants: UNIVERSITÉ DE TOURS, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)Inventors: Nathalie HEUZE-VOURC'H, Thomas SECHER, Muriel THOMAS
-
Patent number: 11819492Abstract: The present invention relates to a compound of the following general formula (I): or a pharmaceutically acceptable salt and/or solvate thereof, for use as drug, particularly intended for inhibiting a programmed cell death route selected from the group consisting of ferroptosis, oxytosis and cellular necroptosis. The present invention also relates to a compound of general formula (I) for use as a drug for neuroprotection as well as for preventing and/or treating disorders associated with cellular necroptosis or ferroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.Type: GrantFiled: December 10, 2021Date of Patent: November 21, 2023Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite, Universite de Poitiers, Centre Hospitalier Universitaire de PoitiersInventors: Stéphane Bach, Marie-Thérèse Dimanche-Boitrel, Claire Delehouze, Thierry Hauet
-
Patent number: 11821044Abstract: The present invention relates to methods for screening a subject for a cancer. In particular, the present invention relates to a method (A) for screening a subject for a cancer comprising the steps of i) extracting the cell free nucleic acids from a sample obtained from the subject, ii) determining the total concentration of mitochondrial cell free nucleic acids, ii) determining the total concentration of nuclear cell free nucleic acids iv) calculating the ratio of the level determined at step ii) to the concentration determined at step iii), v) comparing ratio determined at step iv) with a predetermined corresponding reference value and vi) concluding that the subject suffers from a cancer when the ratio determined at step iv) is lower than the predetermined corresponding reference value or concluding that the subject does not suffer from a cancer when the ratio determined at step iv) is higher than the predetermined corresponding reference value.Type: GrantFiled: June 23, 2020Date of Patent: November 21, 2023Assignees: INSTITUT NATIONAL DE LA SANTÈ ET DE LA RECHERCHE MÈDICALE, INSTITUT REGIONAL DU CANCER DE MONTPELLIER, UNIVERSITE DE MONTPELLIERInventors: Alain Thierry, Safia El Messaoudi